Presiding: Margaret M. Dunn, Dean

Present: Drs. Linda Barney, Eric Bennett, Jim Brown, John Duby, Kim Gilliam, Mike Johnson, Michael Leffak, Col. Brad Lloyd, Al Painter, Brenda Roman, Daniel Swagerty, Jeff Travers, Randy Woods, and Jerry Yaklic

Staff: Joanna Anderson, Angela Clements, Drew Dieckman and Kim Paul

The meeting was called to order at 4:35 p.m. by Dean Margaret Dunn

1. **Approval of Minutes:**
   A motion was made, seconded and passed unanimously to approve the minutes of August 8, 2019, as written.

2. **Report of the Dean:**
   A. **Proposal for the creation of the Department of Medical Education:**
      Many other schools have created departments of Medical Education. It would support recruitment of faculty focused on medical educational leadership and research, and could also offer multidisciplinary degrees and certificates. The BSOM faculty was notified of the proposal on August 22 and the proposal must go to the Provost and Faculty Senate before being approved by the University Board of Trustees.
   
   B. **BSOM Visioning Exercise:**
      On Thursday, December 12th from 2:00 p.m. to 8:00 p.m. and Friday, December 13th from 8:00 a.m. to 12:30 p.m., Drs. Dunn and David Bright will be holding a BSOM visioning exercise for the Executive Committee and the CQI Steering Committee. The purpose of this exercise is to take a look at BSOM’s strengths, opportunities, aspirations and results, as part of the preparation for the BSOM leadership transition.
   
   C. **Representative from BSOM to the Faculty Senate’s Library Faculty Advisory Board:**
      The Faculty Senate’s Library Faculty Advisory Board is in need of a representative from BSOM. The Advisory Board meets twice in the fall and twice in the spring. The projects this year include a faculty survey and providing input on the University Library’s strategic Plan. Please send the names of any interested faculty members to Dr. Dunn.

3. **Information Items:**
   A. **Personnel Actions:**
      Dr. Painter presented the personnel action items that were distributed with the agenda. A motion was made, seconded and unanimously approved to accept the personnel actions as distributed.
B. Members’ Items:

- Dr. Painter: The BSOM Women Faculty Collaborative are hosting their first event to celebrate women faculty and developing their future in medicine. The event will be held on Monday, October 21st from 5:30 p.m. to 7:30 p.m. at the Wandering Griffin and will feature a panel presentation by Drs. Dunn, Kadakia and Roman. Please encourage your female faculty members to attend.

- Dr. Bennett: COSM Festival of Research is on Friday, September 20th. The Festival of Research showcases the research endeavors of faculty, staff, and students supported by COSM. At 3 p.m. there will be research poster displays as part of the Ohio Physiological Society meeting which will continue through September 21st.

New Business:

A. Scholarship in Medicine Update – Jeffrey Travers, M.D., Ph.D., Professor and Chair, Pharmacology & Toxicology

B. CQI Steering Committee Update – Brenda Roman, M.D., Associate Dean for Medical Education

5. Adjournment:

There being no further business, the meeting was adjourned at 5:35 p.m.

The next scheduled meeting is Thursday, October 10, 4:30 p.m. in the WSP Health Center, 725 University Blvd., Third Floor, Large Conference Room.

Respectfully submitted,

Drew Dieckman
Recorder
Title of Project
Student Name
Mentor Name and Affiliation
Track
Scholarship in Medicine Proposal

☐ By checking this box, I indicate that my mentor has read and reviewed my draft proposal prior to submission

*Students should use the AMA template on BAMS for writing the proposal and final report.*

Abstract

(pose clinical question/diagnostic problem, provide essential information about the case)

Key Words: (list 3-10 key words here)

Introduction/Literature Review

(Provide a brief background and rationale for your proposed case. Introduce your topic, the significance, and gaps in the literature.)

Clinical Question

(State the clinical question or diagnostic problem)

Case Description/Summary

*History and Presentation*

(How did the patient present?)

*Diagnostic Focus and Assessment*

(What were the steps that led toward the diagnosis? What was the thought process? What were the test results?)

*Therapeutic Focus and Assessment*

(What therapies were tried? What were consultant recommendations? What worked, what did not?)

*Follow-up and Outcome*

(What was the final result? What adverse results were noted? How did the patient adhere to treatment?)

Analysis of Diagnostic Assessment/Therapeutic Interventions

(For each of the following, if relevant, discuss the sensitivity, specificity, number needed to treat, positive predictive value, and/or negative predictive value for each of the diagnostic
assessments (physical exam, labs, scans, etc.) and therapeutic interventions (medications, physical therapy, surgeries, etc.) listed above. Why did you select those assessments and interventions? How were your choices supported by the literature?)

Discussion and Connection to Literature

(Discuss the summary of the case and its results. Discuss the importance of the case. Describe the existing theories and research findings on the key issue in the patient's condition. Include a thorough connection to the existing literature and known epidemiology of the case. Explain how this evidence can add value to future clinical practice.)

Conclusion

(Summarize the case. What are the important lessons learned?)

Patient Perspective

(What was the patient’s experience? State that the patient provided informed consent)

Timeline of your involvement in the project

(Expected timeline for getting ethical approval, reviewing/investigating the literature, collecting data, analyzing data etc.)

Goals of the Case Report

(Explain the value of your case report in one or more of the following areas:

- Recognition and description of a new disease
- Recognition of rare manifestations of a known disease
- Elucidation of the mechanisms of a disease
- Detection of adverse or beneficial side effects of drugs (and other treatments)
- Medical education and audit)

Role of Student

(Specifically, in which areas you will participate. Be detailed about how you’re involved. The paper that will be turned in for SCH credit MUST be the student’s original work.)

Plan for Ethical Approval

(If your project involves human or animal subjects, state when you will apply for IRB/IACUC approval. State that the patient provided informed consent.)

(If your project already has approval, list the number and approval date.)

References

- (In AMA format.)
- (All references listed here should be cited (in-text citations) in the Introduction/Literature Review or Discussion sections.)
- (At least 5 appropriate sources)
CASE REPORT

An aberrant reaction to Candida albicans antigen used for recalcitrant warts successfully treated with oral prednisone

Andrew La'Pelusa, BS, Jennifer Rorex, BS, Nathan M. Weir, MD, PhD, and Jeffrey Bryant Travers, MD, PhD

Dayton, Ohio

Key words: immune therapy; papillomavirus.

INTRODUCTION
Cutaneous papillomavirus infections are a common cause of morbidity. Although many treatment regimens for common warts are available, no single form of therapy is the clear method of choice. Immunotherapy with Candida albicans antigen injections is an accepted method that can be effective, with few side effects reported. The immunotherapeutic Candida antigen (CA), is used intralesionally for the treatment of recalcitrant warts. Candida antigen induces a delayed hypersensitivity reaction in healthy patients such that the cell-mediated immune response enhances the immune system’s identification of the viral infection. Although safe, previous studies report pain, edema, and a purple digit as rare aberrant reactions to such treatment.

CASE REPORT
An 11-year-old, 56.3-kg girl with a 5-mm verru­cous papule with thrombosed capillaries on the lateral distal right fifth digit presented to the clinic with concerns for wart removal. After unsuccessful treatment with cryotherapy, the patient and her mother were provided education about the immunotherapeutic CA. At the time of the first treatment approximately 2 months after cryotherapy, not only did the patient receive a 0.1-mL of 50 μm/mL CA (LETI Laboratories, Barcelona, Spain) into finger, we also injected 0.1 mL of CA into the ipsilateral volar forearm as a test site.

The patient and family were instructed to obtain a picture of the volar forearm test site 2 days later. At her follow-up appointment 1 month later, the family noted a minimal reaction from the injections (less

Fig 1. Photo taken 2 days after the second 0.1-mL injection of CA into the fifth digit. The patient experienced redness, edema, and mild pain.
Fig 2. The patient reported an improvement at the end of a tapering dose of oral prednisone regimen (see text for dosage).

than 5 mm from the provided digital picture of forearm test site), and the wart was approximately the same size (5 mm). At this visit, the recalcitrant wart was treated with a second injection of 0.1 mL CA. Later that night, the patient was taken to urgent care by her mother with the reported concern of redness, pain, and edema in the digit. The patient was given ibuprofen, 200 mg 3 times a day. One day later the finger worsened with increased swelling and mild pain (Fig 1). Two days after the injection, the patient was seen in the clinic and examined. It was noted that there was no dysesthesias of the tip of the affected finger as would be associated with compartment syndrome. The patient was then started on a tapering dose of oral prednisone: five 10-mg tablets of oral prednisone per day for 3 days, three 10-mg tablets of oral prednisone per day for 3 days, and one 10-mg tablet of oral prednisone per day for 3 days. The patient reported an improvement at the end of the treatment regimen (Fig 2). Approximately 2 months later, the finger was asymptomatic, although slight erythema was noted (Fig 3). The wart resolved.

DISCUSSION

Although considered safe, CA antigen is reported to cause exuberant reactions in some cases. Of interest, this reaction might be dose dependent, with less chance of reaction using diluted CA antigen. Neither the original test site nor the first wart injection resulted in significant inflammation. This finding suggests that having a minimal antecedent reaction does not predict a future exuberant one.

We report this case to increase awareness of the possible complications that may arise when using CA antigen in an otherwise healthy patient. Moreover, as no specific treatment (other than surgical incision to the area because of worries about compartment syndrome) was described in original reports of CA reactions, this report indicates that a course of systemic prednisone at 1 mg/kg with rapid taper has efficacy.

Fig 3. Approximately 2 months after the oral prednisone treatment, the finger exhibited mild erythema and was otherwise asymptomatic with resolution of the wart.

REFERENCES

BSOM Continuous Quality Improvement Steering Committee (CQISC)

Executive Summary
September 2019

Since the last report to the Executive Committee in March, the CQISC has reviewed and discussed the following items:

- Spent the majority of time from April-July reviewing all as well as developing several new medical student policies that needed to be in place before the current academic year
- August CQI meeting focused on “hot topics” related to LCME elements and these will be divided up amongst the CQI committee members to begin reviewing data (including internal ISA evaluations, annual AAMC GQ surveys) and writing up drafts for the DCI narratives
  - Essentially treating the DCI as a “living document” so that we can identify areas for improvement and make changes PRIOR to completing the formal DCI paperwork ~18 months prior to our next site visit (March 2025)
- Reviewed “progress reports” for the four elements that we have to submit updates to the LCME next summer 2020 during the September CQI meeting
  - 3.3 Diversity – specifically recruitment & retention programming for faculty, senior leadership
  - 7.9 Interprofessional Education
  - 11.1 Academic Advising
  - 11.2 Career Advising – need to put together focus groups with students to better identify areas for improvement in this area
- Welcomed new members to the committee this year:
  - Paul Koles, MD, Department Chair, Pathology
  - Amber Todd, PhD, Director of Assessment, OME
  - Kriti Goel, M3 student representative
  - Aaron Blevins, M2 student representative

Any questions or comments for the CQI steering committee or about LCME can be directed to Dr. Brenda Roman (brenda.roman@wright.edu) or Colleen Hayden (colleen.hayden@wright.edu) in the Office of Medical Education.
<table>
<thead>
<tr>
<th>LCME &quot;HOT TOPICS&quot;</th>
<th>Primary Reviewer</th>
<th>Assistant Reviewer</th>
<th>AGENDA MONTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.6 Serving-Learning/Community Service</td>
<td>Aaron Blevins</td>
<td>Colleen Hayden</td>
<td>November-19</td>
</tr>
<tr>
<td>9.9 Student Advancement and Appeal Process</td>
<td>Al Painter</td>
<td>Brenda Roman</td>
<td>November-19</td>
</tr>
<tr>
<td>8.7 Comparability of Education/Assessment</td>
<td>Gary LeRoy</td>
<td>Brenda Roman</td>
<td>November-19</td>
</tr>
<tr>
<td>9.3 Clinical Supervision of Medical Students</td>
<td>Randy Welton</td>
<td>Brenda Roman</td>
<td>November-19</td>
</tr>
<tr>
<td>9.5 Narrative Assessment</td>
<td>Aaron Blevins</td>
<td>Colleen Hayden</td>
<td>January-20</td>
</tr>
<tr>
<td>1.4 Affiliation Agreements</td>
<td>Amber Todd</td>
<td>Colleen Hayden</td>
<td>January-20</td>
</tr>
<tr>
<td>12.6 Student Health and Disability Insurance</td>
<td>Kim Paul</td>
<td>Colleen Hayden</td>
<td>January-20</td>
</tr>
<tr>
<td>9.7 Formative Assessment and Feedback</td>
<td>Kriti Goel</td>
<td>Colleen Hayden</td>
<td>January-20</td>
</tr>
<tr>
<td>6.2 Required Clinical Experiences</td>
<td>Kriti Goel</td>
<td>Brenda Roman</td>
<td>February-20</td>
</tr>
<tr>
<td>10.4 Characteristics of Accepted Applicants</td>
<td>Al Painter</td>
<td>Brenda Roman</td>
<td>February-20</td>
</tr>
<tr>
<td>9.1 Preparation of Resident and Non-Faculty Instructors</td>
<td>Randy Welton</td>
<td>Brenda Roman</td>
<td>February-20</td>
</tr>
<tr>
<td>*7.9 Interprofessional Collaborative Skills</td>
<td>Aaron Blevins</td>
<td>Brenda Roman</td>
<td>March-20</td>
</tr>
<tr>
<td>*3.3 Diversity/Pipeline Programs and Partnerships</td>
<td>Amber Todd</td>
<td>Brenda Roman</td>
<td>March-20</td>
</tr>
<tr>
<td>*11.1 Academic Advising</td>
<td>Eric Bennett</td>
<td>Colleen Hayden</td>
<td>March-20</td>
</tr>
<tr>
<td>*11.2 Career Advising</td>
<td>Randy Welton</td>
<td>Colleen Hayden</td>
<td>March-20</td>
</tr>
<tr>
<td>8.4 Evaluation of Education Program Outcomes</td>
<td>Al Painter</td>
<td>Colleen Hayden</td>
<td>April-20</td>
</tr>
<tr>
<td>8.1 Curricular Management</td>
<td>Amber Todd</td>
<td>Brenda Roman</td>
<td>April-20</td>
</tr>
<tr>
<td>8.3 Curricular Design, Review, Revision/Content Monitoring</td>
<td>Eric Bennett</td>
<td>Brenda Roman</td>
<td>April-20</td>
</tr>
<tr>
<td>8.2 Use of Medical Educational Program Objectives</td>
<td>Paul Koles</td>
<td>Colleen Hayden</td>
<td>April-20</td>
</tr>
<tr>
<td>8.6 Monitoring of Completion of Required Clinical Experiences</td>
<td>Gary LeRoy</td>
<td>Brenda Roman</td>
<td>May-20</td>
</tr>
<tr>
<td>2.4 Sufficiency of Administrative Staff</td>
<td>Kim Paul</td>
<td>Colleen Hayden</td>
<td>May-20</td>
</tr>
<tr>
<td>7.3 Scientific Method/Clinical/Translational Research</td>
<td>Paul Koles</td>
<td>Colleen Hayden</td>
<td>May-20</td>
</tr>
<tr>
<td>6.3 Self-Directed and Life-Long Learning</td>
<td>Randy Welton</td>
<td>Brenda Roman</td>
<td>May-20</td>
</tr>
<tr>
<td>3.1 Resident Participation in Medical Student Education</td>
<td>Al Painter</td>
<td>Brenda Roman</td>
<td>June-20</td>
</tr>
<tr>
<td>6.7 Academic Environments</td>
<td>Amber Todd</td>
<td>Brenda Roman</td>
<td>June-20</td>
</tr>
<tr>
<td>3.6 Student Mistreatment</td>
<td>Eric Bennett</td>
<td>Brenda Roman</td>
<td>June-20</td>
</tr>
<tr>
<td>3.5 Learning Environment/Professionalism</td>
<td>Paul Koles</td>
<td>Brenda Roman</td>
<td>June-20</td>
</tr>
<tr>
<td>1.5 Bylaws</td>
<td>Greg Kojola</td>
<td>Colleen Hayden</td>
<td>July-20</td>
</tr>
<tr>
<td>11.6 Student Access to Educational Records</td>
<td>Greg Kojola</td>
<td>Colleen Hayden</td>
<td>July-20</td>
</tr>
<tr>
<td>1.2 Conflict of Interest Policies</td>
<td>Paul Koles</td>
<td>Brenda Roman</td>
<td>July-20</td>
</tr>
<tr>
<td>1.1 Strategic Planning and Continuous Quality Improvement</td>
<td>Eric Bennett</td>
<td>Colleen Hayden</td>
<td>August-20</td>
</tr>
<tr>
<td>4.6 Responsibility for Medical School Policies</td>
<td>Greg Kojola</td>
<td>Colleen Hayden</td>
<td>August-20</td>
</tr>
<tr>
<td>11.5 Confidentiality of Student Educational Records</td>
<td>Kim Paul</td>
<td>Colleen Hayden</td>
<td>August-20</td>
</tr>
</tbody>
</table>

*currently on monitoring for these elements*